Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Journal of Neuro-Oncology|April 7, 2006
The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumorsJos M A Kuijlen, Bart J de Haan, Wijnand Helfrich, et al.
Immunology Letters|April 26, 2011
Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signalingEdwin Bremer, Wayel H Abdulahad, Marco de Bruyn, et al.
Arthritis Research & Therapy|December 17, 2011
Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjectsPaul Eggleton, Edwin Bremer, Joanna M Tarr, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic eliminationJanet E Holley, Edwin Bremer, Alexandra C Kendall, et al.
The Cochrane Database of Systematic Reviews|September 11, 2018
Antigen-specific active immunotherapy for ovarian cancerSterre T Paijens, Ninke Leffers, Toos Daemen, et al.
Molecular Cancer|November 25, 2010
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivoMarco de Bruyn, Anna A Rybczynska, Yunwei Wei, et al.
Oncoimmunology|July 3, 2015
CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancerMarco de Bruyn, Valerie R Wiersma, Maartje C A Wouters, et al.
Journal for Immunotherapy of Cancer|September 21, 2023
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFREmily Maria Ploeg, Douwe Freerk Samplonius, Xiao Xiong, et al.
International Journal of Cancer|April 12, 2002
Tumor-targeted immune complex formation: effects on myeloid cell activation and tumor-directed immune cell migrationBart-Jan Kroesen, Pamela M J McLaughlin, Petra H L Schuilenga-Hut, et al.
Cancer Letters|August 31, 2021
Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesiclesEmily M Ploeg, Xiurong Ke, Isabel Britsch, et al.
Pageof 8